Abstract
Purpose: Long-term survivors of Ewing sarcoma (ES) and osteosarcoma may be at risk for therapy-related acute leukemia or myelodysplastic syndrome (t-AL/MDS).
Methods and Materials: We retrospectively reviewed the clinicopathologic characteristics of 1071 patients with osteosarcoma (n = 757) and ES (n = 314) who were treated between 1985 and 2014. Multivariable competing risk analysis was used to analyze predictors of t-AL/MDS, including a radiation dose (>= 55.8 Gy vs <55.8 Gy) x disease site (pelvis/spine vs other) interaction term. A supplemental nested case-control study was conducted to assess the association between cumulative chemotherapy dose and t-AL/MDS.
Results: The median follow-up for surviving patients was 97 months (range, 0.03-380). Twenty patients developed t-AL/MDS, all of whom received chemotherapy and 15 of whom were treated with radiation therapy. Radiation therapy to >= 55.8 Gy was associated with development of t-AL/MDS (adjusted hazard ratio, 2.89; 95% confidence interval [CI], 1.23-6.80; P = .015), and there was a significant radiation dose x disease site interaction term (adjusted hazard ratio, 6.70; 95% CI, 2.71-16.53; P-interaction < .001). The 5-year cumulative incidence of t-AL/MDS in patients receiving >= 55.8 Gy radiation therapy to the pelvis or spine was 5.0% 95% CI, 0.9-14.9) for osteosarcoma and 10.7% for ES 95% CI, 3.3-23.2). In our nested case-control study, cumulative doses of ifosfamide and etoposide were associated with development of t-AL/MDS.
Conclusions: Patients with osteosarcoma and ES receiving >= 55.8 Gy of radiation therapy to the pelvis or spine appear to be at increased risk for t-AL/MDS. Treatment with high cumulative doses of chemotherapy may further augment this risk. (C) 2018 Published by Elsevier Inc.
